Treatment of inferior lateral pterygoid muscle dystonia with zolpidem tartrate, botulinum toxin injections, and physical self-regulation procedures: A case report

Cranio - Journal of Craniomandibular and Sleep Practice

Volumn 22, Issue 4, 2004, Pages 325-329

  Vazquez Delgado, Eduardo ^a,b,c   Okeson, Jeffrey P ^a,d,e  

^a UNIVERSITY OF KENTUCKY COLLEGE OF DENTISTRY   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

^c CENTRO MÉDICO TEKNON   (Spain)

^d UNIVERSITY OF KENTUCKY   (United States)

^e Orofacial Pain Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMANTADINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; CITRATE CALCIUM; CLONAZEPAM; CYCLOBENZAPRINE; ENALAPRIL; FLUOXETINE; GABAPENTIN; HYDROXYZINE; LORAZEPAM; RALOXIFENE; SERTRALINE; SOTALOL; TIZANIDINE; TRIHEXYPHENIDYL; ZOLPIDEM TARTRATE;

ADULT; ARTICLE; CASE REPORT; DRUG EFFICACY; DRUG SAFETY; DYSTONIA; FEMALE; HUMAN; MASTICATORY MUSCLE; RELAXATION TRAINING; SIDE EFFECT; TREATMENT OUTCOME;

EID: 9144253912     PISSN: 08869634     EISSN: None     Source Type: Journal    
DOI: 10.1179/crn.2004.041     Document Type: Article

References (31)

1. Tan EK, Jankovic J: Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurol 1999; 53(9):2102-2107.
2. Sforza E, Montagna P, Defazio G, Lugaresi E: Sleep and cranial dystonia. Electroencephalogr Clin Neurophysiol 1991; 79(3):166-169.
3. Sharma AK, Behari M, Ahuja GK: Clinical and demographic features of Meige's syndrome. J Assoc Physicians India 1996; 44(9):645-647.
4. Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ III: Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 1988; 3(3):188-194.
5. Berardelli A, Rothwell JC, Day BL, Marsden CD: Pathophysiology of blepharospasm and oromandibular dystonia. Brain 1985; 108(Pt 3):593-608.
6. Defazio G, Lamberti P, Lepore V, Livrea P, Ferrari E: Facial dystonia: clinical features, prognosis, and pharmacology in 31 patients. Ital J Neurol Sci 1989; 10(6):553-560.
7. Tolosa E, Marti MJ: Blepharospasm-oromandibular dystonia syndrome (Meige's syndrome): clinical aspects. Adv Neurol 1988; 49:73-84.
8. Esper GJ, Charles PD, Davis TL, Robertson D: Adult-onset focal dystonias: presentation and treatment options. Tenn Med 1997; 90(1): 18-20.
9. Steinberger D, Topka H, Fischer D, Muller U: GCH1 mutation in a patient with adult-onset oromandibular dystonia. Neurol 1999; 52(4):877-879.
10. Lee LV, Kupke KG, Caballar-Gonzaga F, Hebron-Ortiz M, Muller U: The phenotype of the X-linked dystonia-parkinsonism syndrome. An assessment of 42 cases in the Philippines. Medicine (Baltimore) 1991; 70(3):179-187.
11. Gouider-Khouja N, Miladi N, Belal S, Hentati F: Intrafamilial phenotypic variability of Hallervorden-Spatz syndrome in a Tunisian family. Parkinsonism Relat Disord 2000; 6(3):175-179.
12. Jankovic J, Ford J: Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol 1983; 13(4):402-411.
13. Ransmayr G, Kleedorfer B, Dierckx RA, Poewe W, Kemmler GW, Gerstenbrand F: Pharmacological study in Meige's syndrome with pre-dominant blepharospasm. Clin Neuropharmacol 1988; 11(1):68-76.
14. Casey DE: Pharmacology of blepharospasm-oromandibular dystonia syndrome. Neurol 1980; 30(7 Pt 1):690-695.
15. Sutcher HD, Underwood RB, Beatty RA, Sugar O: Orofacial dyskinesia. A dental dimension. JAMA 1971; 216(9):1459-1463.
16. Jankovic J, Schwartz K, Donovan DT: Botulinum toxin treatment of cranial cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psych 1990; 53(8):633-639.
17. Poungvarin N, Devahastin V, Chaisevikul R, Prayoonwiwat N, Viriyavejakul A: Botulinum A toxin treatment for blepharospasm and Meige syndrome: report of 100 patients. J Med Assoc Thai 1997; 80(1):1-8.
18. Behari M, Singh KK, Seshadri S, Prasad K, Ahuja GK: Botulinum toxin A in blepharospasm and hemifacial spasm. J Assoc Physicians India 1994; 42(3):205-208.
19. Blitzer A, Brin MF, Greene PE, Fahn S: Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol 1989; 98(2):93-97.
20. Okeson JP: Management of temporomandibular disorders and occlusion. 5th ed. St. Louis: Mosby, 2003.
21. Laskawi R, Rohrbach S: Oromandibular dystonia. Clinical forms, diagnosis and examples of therapy with botulinum toxin. Laryngorhinootologie 2001; 80(12):708-713.
22. Evidente VG: Zolpidem improves dystonia in "Lubag" or X-linked dystonia parkinsonism syndrome. Neurol 2002; 58(4):662-663.
23. Moreno-Lopez B, de la Cruz RR, Pastor AM, Delgado-Garcia JM, Alvarez FJ: Effects of botulinum neurotoxin type A on the expression of gephyrin in cat abducens motoneurons. J Comp Neurol 1998; 400(1):1-17.
24. Hipola D, Mateo D, Gimenez-Roldan S: Meige's syndrome: acute and chronic responses to clonazepam and anticholinergics. Eur Neurol 1984; 23(6):474-478.
25. Ruzicka E, Roth J, Jech R, Busek P: Subhypnotic doses of zolpidem oppose dopaminergic-induced dyskinesia in Parkinson's disease. Mov Disord 2000; 15(4):734-735.
26. Langer SZ, Arbilla S, Scatton BV, Niddam R, Dubois A: Receptors involved in the mechanism of action of zolpidem. In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1988:55-70.
27. Benavides J, Peny B, Ruano D, Vitorica J, Scatton B: Comparative autoradiographic distribution of central omega (benzodiazepine) modulatory site subtypes with high, intermediate and low affinity for zolpidem and alpidem. Brain Res 1993; 604(1-2):240-250.
28. Vitek JL: Pathophysiology of dystonia: a neuronal model. Mov Disord 2002; 17 [Suppl] 3:S49-S62.
29. Bressman SB: Dystonia update. Clin Neuropharmacol 2000; 23(5):239-251.
30. Nobrega JN, Richter A, Burnharn WM, Loscher W: Alterations in the brain GABAA/benzodiazepine receptor-chloride ionophore complex in a genetic model of paroxysmal dystonia: a quantitative autoradiographic analysis. Neuroscience 1995; 64(1):229-239.
31. Perrault G, Morel E, Sanger DJ, Zivkovic B: The interaction between zolpidem and beta-CMC: a clue to the identification of receptor sites involved in the sedative effect of zolpidem. Eur J Pharmacol 1988; 156(2):189-196.